Multi-modal Adverse Events Prediction for Premature Coronary Heart Disease Trial: MAP-CHD Trial
NCT ID: NCT07004452
Last Updated: 2025-06-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
5000 participants
OBSERVATIONAL
2025-03-31
2027-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
* What are the major risk factors for poor prognosis in Chinese patients with premature coronary artery disease?
* What is the difference in the prognosis of patients with premature coronary heart disease with different phenotypes? Participants taking no mandatory intervention will be followed up for 2 year, with blood tests at 1 year and outpatient or telephone interviews at other timepoints.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Multi-omics Study of "Healthy" Premature CAD Patients
NCT06362278
Personalized Risk Evaluation and Diagnosis (Using Corus CAD or ASGES) in the Coronary Tree
NCT00500617
Development, Testing, and Validation of A Protocol To Assess Cardiovascular Reactivity in Human Populations
NCT00005231
Clinical and Genetic Characteristics of Coronary Artery Disease in Chinese Young Adults
NCT02496858
The Young Heart Study
NCT04462159
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Clinically confirmed CAD with ≥50% luminal stenosis in at least one major coronary artery or significant branch, verified by coronary angiography;
* For acute coronary syndrome (ACS) or percutaneous coronary intervention (PCI) patients: clinical stability meeting discharge criteria post-treatment;
* Voluntary participation with signed informed consent.
Exclusion Criteria
* Severe systemic comorbidities with life expectancy \<1 year;
* Previous enrollment in other drug/device clinical trials without completing the primary endpoint observation period;
* Inability to comply with follow-up (e.g., dementia, severe psychiatric disorders).
18 Years
45 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
China National Center for Cardiovascular Diseases
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
FuWai Hospital
Beijing, , China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2023ZD0504003
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.